Rui-lian Chen

The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.

Li-Zhu Lin, M. Jiang, Yang Cao, 2019, Immunotherapy.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival

Li-Zhu Lin, Zhiwei Xiao, Lingling Sun, 2020, Frontiers in Immunology.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical lung cancer.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Jian Su, Jun Zhao, Qing Zhou, 2018, BMC Cancer.

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

Li-Zhu Lin, W. Hou, Hanrui Chen, 2021, Frontiers in Oncology.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, BMC Cancer.